Omega-3 / Fish Oil for Depression

Verdict: Works only as high-EPA add-on

For depression, omega-3 helps only as an adjunct to standard treatment, and only when the formula is EPA-dominant and dosed high enough; it is not a standalone cure, and DHA-heavy products do nothing.

B 🟡 B Preliminary Evidence Published

🔬Why this grade7-layer evidence engine

The evidence earns a Preliminary (Tier B) grade because benefit is real but narrowly conditional. A high-quality 2019 meta-analysis (PMID 31383846, n=2,160) found a modest pooled effect (SMD -0.28) that grew much larger for EPA-pure (SMD -0.50) and EPA-major formulas (SMD -1.03), while DHA-dominant products showed no benefit over placebo. This formulation split is the single most important caveat.

Dose and patient type matter just as much. A government-funded dose-finding RCT (PMID 36005883) saw a meaningful response only at EPA 4 g/day (Cohen d=0.53), with 1-2 g/day no better than placebo and the effect concentrated in patients with high inflammation. A 2025 review (PMID 39912390) echoed that higher-EPA doses help most in inflammatory, late-life, or cardiac-comorbid depression. In children and adolescents, a 2024 systematic review (PMID 39564892) found no significant effect (very low certainty).

It is not Tier A because no major regulator (FDA, EFSA, NHS, WHO) authorizes any depression claim, and clinical bodies stay cautious: Mayo Clinic states fish oil alone is not a depression treatment, while Harvard, Cleveland Clinic, and the ADAA frame EPA-rich omega-3 (about 1-2 g/day, EPA >=60%) as an adjunct alongside, not instead of, proven therapy. Evidence also points against using it to prevent depression.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.59
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published
Confidence
85%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.595
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Efficacy of omega-3 PUFAs in depression: A meta-analysis
PMID: 31383846 2019 統合分析 n = 2,160
Finding: Overall SMD = -0.28 (p=0.004); EPA-pure SMD = -0.50 (p=0.003); EPA-major SMD = -1.03 (p=0.03); DHA formulations showed no significant benefit vs placebo
🟢 High quality Academic Effect size: [object Object]
View on PubMed
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Randomized Dose-Finding Clinical Trial
PMID: 36005883 2022 RCT (double-blind) n = 61
Finding: EPA 4 g/d response rate 64% vs 40% placebo (OR=2.63, Cohen d=0.53); 1-2 g/d arms NOT significantly different from placebo; hs-CRP reduction correlated with symptom reduction (Spearman rho=0.691, p=0.019)
🟢 High quality Government Effect size: [object Object]
View on PubMed
Omega-3 fatty acid supplementation for depression in children and adolescents
PMID: 39564892 2024 系統性回顧 n = 228
Finding: Self-reported symptoms SMD = -0.34 (95% CI -0.85 to 0.17, very low-certainty); remission OR = 1.11 (95% CI 0.45-2.75, NS); minor AEs (cramps, GI)
Academic Effect size: [object Object]
View on PubMed
Omega-3 polyunsaturated fatty acids in depression: insights from recent clinical trials
PMID: 39912390 2025 系統性回顧
Finding: Higher EPA doses (>1 g/day) improved depression measures, particularly in MDD with elevated inflammation, comorbid CVD, late-life onset, and pediatric populations; EPA-dominant superior to DHA-dominant
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
Generally Recognized As Safe (GRAS) - authorized under 21 CFR 184.1472 source↗
L4b EU EFSA
Supportive
intakes of 250mg a day sufficient for normal cardiac function source↗
L4c UK NHS
Neutral
at least 2 portions of fish a week, including 1 of oily fish source↗
L4d TW TFDA / 衛福部
Supportive
每日攝取量所含之ω-3脂肪酸至少應達一.○克 source↗
L4e WHO
Neutral
2 g/day of purified omega-3 fatty acids offer substantial advantages source↗
L5a NIH Office of Dietary Supplements
Supportive
ALA is an essential fatty acid source↗
L5b Mayo Clinic
Cautious
fish oil alone isn't a depression treatment source↗
L5c Cleveland Clinic
Cautious
Omega-3 (fish oil) source↗
L5d Harvard Health
Cautious
promising natural treatments for mood disorders source↗
L5e Specialty Society (condition-mapped)
Supportive
used alone or in conjunction with standard antidepressants source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-depression-INT-omega-3-fatty-acids-001 繁體中文版 →